⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1360451 | 0.78 | — | — | |
| SCHEMBL1776736 | 0.78 | — | — | |
| SCHEMBL1155869 | 0.78 | — | — | |
| SCHEMBL1802524 | 0.78 | — | — | |
| 1,3,5-Trichlorobenzene SCHEMBL7529975 | 0.76 | TSHR (0.57) | — | |
| SCHEMBL22316707 | 0.67 | TDO2 (0.36) | — | |
| SCHEMBL221839 | 0.67 | — | — | |
| SCHEMBL1531580 | 0.67 | — | — | |
| SCHEMBL3611423 | 0.67 | — | — | |
| SCHEMBL1319669 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1914182-B | Quinazoline derivatives | ASTRAZENECA AB | 2011-09-07 | — | — | CN | claimed |
| US-7632840-B2 | Quinazoline compounds for the treatment of hyperproliferative disorders | ASTRAZENECA AB (SE) | 2009-12-15 | — | — | US | claimed |
| EP-1713781-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-11-05 | — | — | EP | claimed |
| US-20070293490-A1 | Quinazoline Derivatives | ASTRAZENECA AB (SE) | 2007-12-20 | — | — | US | claimed |
| JP-2007523072-A | — | — | 2007-08-16 | — | — | JP | claimed |
| CN-1914182-A | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2007-02-14 | — | — | CN | claimed |
| EP-1713781-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2006-10-25 | — | — | EP | claimed |
| WO-2005075439-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | claimed |
| US-8735410-B2 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2014-05-27 | — | — | US | disclosed |
| CN-101128456-B | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB | 2013-01-23 | — | — | CN | disclosed |
| CN-1914182-B | Quinazoline derivatives | ASTRAZENECA AB | 2011-09-07 | — | — | CN | disclosed |
| EP-1856095-B1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2011-08-24 | — | — | EP | disclosed |
| US-20110152297-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | Astra Zeneca AB Corporation | 2011-06-23 | — | — | US | disclosed |
| US-7632840-B2 | Quinazoline compounds for the treatment of hyperproliferative disorders | ASTRAZENECA AB (SE) | 2009-12-15 | — | — | US | disclosed |
| US-20070293490-A1 | Quinazoline Derivatives | ASTRAZENECA AB (SE) | 2007-12-20 | — | — | US | disclosed |
| EP-1856095-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | AstraZeneca AB (SE) | 2007-11-21 | — | — | EP | disclosed |
| CN-1914182-A | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2007-02-14 | — | — | CN | disclosed |
| EP-1713781-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2006090163-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-08-31 | — | — | WO | disclosed |
| WO-2005075439-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |